ArticleRespiratory research2025
The importance of considering progression speed in systemic sclerosis-associated interstitial lung diseases: application of 2022 and 2024 clinical practice guidelines for progressive pulmonary fibrosis, a retrospective cohort study.
Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Incidence and influencing factors of progressive pulmonary fibrosis in connective tissue disease-associated interstitial lung disease: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Systemic Sclerosis-Associated ILD: Insights and Limitations of ScleroID.Diagnostics (Basel, Switzerland) · 2026Article
- Type I interferon pathway activation in connective tissue disease associated interstitial lung disease.Frontiers in immunology · 2026Review
- Real-world immunosuppressive treatment patterns and disease progression in systemic sclerosis-associated interstitial lung disease.Northern clinics of Istanbul · 2026Article
- Biomarker patterns across skin-lung-gut burden in systemic sclerosis.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic sclerosis (SSc)-associated interstitial lung disease (ILD) evolution is highly heterogeneous. Recent efforts to define progressive pulmonary fibrosis (PPF) have led to a definition including patient's symptoms, pulmonary function tests, and high-resolution computed tomography (HRCT) criteria for progression, occurring over a one-year period (2022 ATS/ERS/JRS/ALAT Guidelines). For SSc-ILD, it has recently been proposed to apply these criteria without a time limit (2024 Guidelines). We aimed to determine the incidence of PPF in a cohort of SSc-ILD using 2022 Guidelines or 2024 Guidelines alternatively, and its impact on survival.
methodsWe conducted a retrospective single center study including patients with SSc-associated ILD diagnosed between 2006 and 2022, with at least one follow-up HRCT and concomitant PFT. All HRCT were centrally reviewed. PPF were defined according to 2022 and 2024 criteria, alternatively. Transplant-free and overall survival were compared using Cox regression models considering progression as a time dependent variable.
resultsAmong 97 patients with SSc-associated ILD, 79 were included in the study, and a total of 279 HRCT were reviewed. The cumulative incidence of progression at 5 years from ILD diagnosis was 22.7% using a 1-year limited definition (2022 criteria) and 45.6% using a definition with no time limit (2024 criteria). Transplant-free survival and overall survival were significantly altered in the group of patients who met 2022 criteria (short-term progressors), in contrast to slow progressors (fulfilling the 2024 criteria but not meeting the 2022 criteria), whose survival did not differ significantly from that of non-progressors.
conclusionOur findings suggest that short-term and slow progressions have distinct prognostic implications and may require dedicated therapeutic management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.